Institutional shares held 15.5 Million
2.3K calls
0 puts
Total value of holdings $11.8M
$1K calls
$0 puts
Market Cap $36.1M
48,720,500 Shares Out.
Institutional ownership 31.74%
# of Institutions 48


Latest Institutional Activity in ENZ

Top Purchases

Q3 2024
Bbr Partners, LLC Shares Held: 100K ($74K)
Q3 2024
Squarepoint Ops LLC Shares Held: 56.6K ($41.9K)
Q3 2024
Bridgeway Capital Management, LLC Shares Held: 181K ($134K)
Q3 2024
Renaissance Technologies LLC Shares Held: 2.53M ($1.87M)
Q3 2024
Citadel Advisors LLC Shares Held: 26.6K ($19.7K)

Top Sells

Q3 2024
Dimensional Fund Advisors LP Shares Held: 304K ($225K)
Q3 2024
Tower Research Capital LLC (Trc) Shares Held: 2.41K ($1.79K)
Q3 2024
Snowden Capital Advisors LLC Shares Held: 10.2K ($7.58K)
Q3 2024
Ubs Group Ag Shares Held: 278 ($206)
Q3 2024
Royal Bank Of Canada Shares Held: 1K ($740)

About ENZ

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ?STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.


Insider Transactions at ENZ

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
399K Shares
From 5 Insiders
Grant, award, or other acquisition 388K shares
Exercise of conversion of derivative security 10.6K shares
Sell / Disposition
76.7K Shares
From 1 Insiders
Payment of exercise price or tax liability 76.7K shares

Track Institutional and Insider Activities on ENZ

Follow ENZO BIOCHEM INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ENZ shares.

Notify only if

Insider Trading

Get notified when an Enzo Biochem Inc insider buys or sells ENZ shares.

Notify only if

News

Receive news related to ENZO BIOCHEM INC

Track Activities on ENZ